bioAffinity Technologies EBITDA par action

Que fait bioAffinity Technologies ? bioAffinity Technologies, Inc. generates revenue through the development of noninvasive diagnostic tests and cancer therapeutics. The company's lead product, CyPath Lung, targets early-stage lung cancer detection without invasive procedures. Through its subsidiary OncoSelect Therapeutics, LLC, it advances cancer therapeutics that selectively target cancer cells. The company focuses on expanding its platform to develop tests for various cancers and potentially other diseases, aiming to address unmet medical needs in oncology. The firm's primary buyers are healthcare providers and medical institutions seeking noninvasive diagnostic solutions for early cancer detection. These institutions purchase CyPath Lung for screening and diagnostic purposes, particularly for lung cancer cases. The company's therapeutic pipeline, developed via OncoSelect Therapeutics, targets healthcare and pharmaceutical partners interested in selective cancer treatments. bioAffinity's development-stage focus means it currently relies on research and development funding rather than commercial sales, with its IPO in 2022 supporting further platform expansion. bioAffinity Technologies, Inc. operates in the medical technology sector, targeting early-stage cancer diagnosis and treatment. Its products are designed to detect cancer through noninvasive means, reducing patient discomfort and enabling earlier intervention. The company's subsidiary OncoSelect Therapeutics drives the development of targeted cancer therapeutics, focusing on selective targeting of diseased cell populations. This approach positions bioAffinity to address significant unmet needs in oncology, particularly for lung cancer diagnostics and therapeutics. bioAffinity Technologies est l'une des entreprises les plus populaires sur Eulerpool.